Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35386132/
2021 Nov 29;4(3):347-349. doi: 10.1016/j.cjco.2021.11.009. 1 Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. 2 Robarts Research Institute, Schulich School of Medicine and Dentistry,...
Conclusion/Relevance: We describe an Ontario patient with HoFH who for 17 months has been treated with monthly infusions of evinacumab added to pre-existing statin, ezetimibe, and evolocumab therapy. Evinacumab in this HoFH patient was associated with markedly improved LDL-C levels and decreased frequency of apheresis.
Share
Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach - The Pharmacogenomics Journal
Source : https://www.nature.com/articles/s41397-022-00274-8
The diagnostic process of familial hypercholesterolemia frequently involves the use of genetic studies. Patients are treated with lipid-lowering drugs, frequently statins. Although pharmacogenomic clinical practice guidelines focusing on genotype-based statin...
Conclusion: This implementation approach facilitates the incorporation of pharmacogenomic studies in clinical care practice, it does not add complexity nor additional steps to laboratory processes, and improves the pharmacotherapeutic process of patients.
Share
Reduced cardiovascular risks in women with endometriosis or polycystic ovary syndrome carrying a common functional IGF1R variant - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35362533/
doi: 10.1093/humrep/deac059. Online ahead of print. 1 Buck Institute for Research on Aging, Novato, CA, USA. 2 Graduate Group in Biostatistics, University of California, Berkeley, School of Public Health, Berkeley,...
Relevance: These findings implicate systemic dysregulation of the insulin-like growth factor-1 axis in the development of HTN, HC and clinical CVD in endometriosis and PCOS, suggesting a common underlying pathogenetic mechanism.
Share
Identification of dominant conformational epitopes from the whole structure of the proprotein convertase subtilisin/kexin type 9 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35339752/
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator of LDLR, has emerged as an important target for the treatment of hypercholesterolemic cardiovascular disease, and monoclonal antibodies alirocumab and evolocumab...
Conclusion: We performed in vitro recombination design on the dominant sequences, and obtained recombinant sequences that can respond to the dominant conformational epitope of PCSK9, which provides a meaningful reference for epitope selection in subsequent PCSK9 vaccine development.
Share
Bile Acid Sequestrants for Hypercholesterolemia Treatment Using Sustainable Biopolymers: Recent Advances and Future Perspectives - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35333534/
Bile acids, the endogenous steroid nucleus containing signaling molecules, are responsible for the regulation of multiple metabolic processes, including lipoprotein and glucose metabolism to maintain homeostasis.
Conclusion: Due to higher daily dosage requirements, lower efficacy in LDL-C reduction, and concomitant drug malabsorption, research to develop an "ideal" BAS from sustainable or natural sources with better LDL-C lowering efficacy and glucose regulations and lower side effects is being pursued. This Review discusses some recent developments...
Share